NEW DELHI: Forty-eight cases of Delta Plus variant of the coronavirus have been detected from 45,000 samples sequenced so far in the country with Maharashtra reporting the highest number of 20, the Centre said on Friday, stressing that there are still very limited cases of this mutation and it cannot be said that it is showing an upward trend.
Delta Plus in Maharashtra: One death recorded, stricter curbs imposed in the state:
Sujit Singh, Director of the National Centre for Disease Control (NCDC), said 20 cases of Delta Plus variant has been found in Maharashtra, followed by nine in Tamil Nadu, seven in Madhya Pradesh, three in Kerala, two each in Punjab and Gujarat, and one case each in Andhra Pradesh, Odisha, Rajasthan, Jammu and Kashmir, and Karnataka.
"There are very limited number of cases of this mutation (Delta Plus). In India, there are very limited cases (of Delta Plus). There are nearly 50 cases that are found in 12 districts and this has happened in the last three months. It cannot be said that in any district, state it is showing an increasing trend. Till the time we don't correlate this we will not say this is a rising trend because its mutations are the same as Delta variant," Singh told a media briefing of the health ministry.
So the transmission variant that is found in Delta can also found in this variant, he added.
ALSO WATCH | How Mumbai, India's most crowded city, beat the odds and the virus
The NCDC is involved in genome sequencing of the coronavirus in the country.
Singh said the Delta Plus variant signifies the Delta variant with an additional mutation -- B.1.617.2.1.
This specifically refers to acquisition of K417N genetic variant in the background of Variant of Concern Delta (B.1.617.2).
He said K417N is of public significance as this mutation is also present in the Variant of Concern Beta (B.1.351).
He said the Delta Plus variant is denoted by a plus sign.
"This does not mean. That severity of transmission is more or lead to more severe disease. If scientific evidence does (suggest) that then we will definitely let you know," he said.
He said Andhra Pradesh, Delhi, Haryana, Kerala, Maharashtra, Punjab, Telangana and West Bengal have Delta variant in more than 50 per cent of the samples sequenced.
"After that, we came to a conclusion that exponential surge during the second wave was to a large extent driven by this variant. Ninety per cent of the cases (of the samples sequenced) are being driven by B.1.617.2 (Delta) variant of SARS-CoV2," he said.
He said coronavirus variants of concern have been found in 174 districts in 35 states and union territories with the highest number of such cases seen in Maharashtra, Delhi, Punjab, Telangana, West Bengal and Gujarat.
The proportion of COVID-19 cases with variants of concern rose from 10.31 per cent in May, 2021 to 51 per cent on June 20, 2021, he added.
The government also asserted that both the COVID-19 vaccines -- Covishield and Covaxin -- work against SARS-CoV-2 variants like Alpha, Beta, Gamma and Delta.
It added that the second wave of COVID-19 is not yet over in country as 75 districts still have more than 10 per cent prevalence and 92 districts have 5-10 per cent prevalence of the coronavirus.
Meanwhile, Maharashtra on Friday reported the first death from the 'Delta Plus' variant of COVID-19, with an octogenarian woman succumbing in Ratnagiri civil hospital, a senior official said.
The woman hails from Sangameswar and was admitted to the hospital, over 330 kilometres from Mumbai, a few days ago, Sanjay Shinde, Additional Collector, Ratnagiri told PTI.
He said the woman's death was being audited to see if she suffered from comorbidities.
Shinde said district officials have been told to increase awareness as well as sensitize people about appropriate COVID-19 behavior.
Forty-eight coronavirus cases of 'Delta Plus' variant have been detected from 45,000 samples sequenced so far in the country, with Maharashtra reporting the highest number of such cases at 20, the Centre said on Friday.
As per a PIB release, the characteristics of the Delta Plus variant include increased transmissibility, stronger binding to receptors of lung cells as well as potential reduction in monoclonal antibody response.